US Stock MarketDetailed Quotes

IMMP Immutep

Watchlist
  • 1.840
  • -0.120-6.12%
Close Nov 21 16:00 ET
  • 1.860
  • +0.020+1.09%
Post 18:51 ET
267.64MMarket Cap-7931P/E (TTM)
Post-Market
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    我要向钱看
    我要向钱看
    Nov 18 00:30
    ON THE WATCH LIST
    $Immutep (IMMP.US)$
    Add AU:IMM to your watchlist
    Immutep Ltd has witnessed a notable increase in its voting power, with Regal Funds Management Pty Limited and its associates now holding 11.79% of the company’s shares, up from 10.59%. This shift, involving various financial entities like UBS and Merrill Lynch, highlights a growing interest in Immutep’s market potential. Investors keen on stock dynamics should keep an eye on these developments for future implications.
    我要向钱看
    我要向钱看
    Nov 15 06:53
    UPDATES
    $Immutep (IMMP.US)$ Baird analyst Joel Beatty maintains $Immutep (IMMP.US)$ with a buy rating, and adjusts the target price from $6 to $7.
    我要向钱看
    我要向钱看
    Nov 14 07:36
    UPDATES
    $Immutep (IMMP.US)$ 
    Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, STS, at the Connective Tissue Oncology Society, CTOS, 2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant se...
    我要向钱看
    我要向钱看
    Nov 14 07:19
    UPDATES
    $Immutep (IMMP.US)$ Immutep Announces Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting; Efti In Combination With Pembrolizumab And Radiotherapy Demonstrates Significant Efficacy In The Neoadjuvant Setting In Patients With Soft Tissue Sarcoma
    我要向钱看
    我要向钱看
    Nov 14 00:00
    UPDATES
    $Immutep (IMMP.US)$ Biotechnology company Immutep (ASX:IMM) obtained positive survival data from the Insight-003 first phase trial, evaluating eftilagimod alpha in combination with Keytruda and chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer, according to a Thursday filing with the Australian bourse.
    The study results, with a minimum follow-up of 22 months, showed a median overall survival of 32.9 months, a median progression-free survival o...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data